Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.74 |
| ▸ | DRD2 | P14416 | 13/20 | 0.72 |
| ▸ | DRD3 | P35462 | 6/20 | 0.72 |
| ▸ | DRD4 | P21917 | 4/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253284 | 0.97 | SLC6A2 (0.74) | SLC6A2SLC6A4DRD2DRD3DRD4 | |
| SCHEMBL15601757 | 0.88 | DRD2 (0.69) | SLC6A2SLC6A4DRD2DRD3DRD4 | |
| SCHEMBL15601686 | 0.85 | DRD2 (0.72) | SLC6A2SLC6A4DRD2DRD3DRD4 | |
| SCHEMBL252085 | 0.84 | HTR1A (0.60) | SLC6A4DRD2DRD3DRD4ADRA1A | |
| SCHEMBL10664987 | 0.84 | DRD2 (1.00) | SLC6A2SLC6A4DRD2DRD3DRD4 | |
| SCHEMBL15601738 | 0.84 | DRD2 (0.87) | SLC6A2SLC6A4DRD2DRD3ADRA1A | |
| SCHEMBL15601769 | 0.83 | DRD2 (0.60) | SLC6A2SLC6A4DRD2DRD3DRD4 | |
| SCHEMBL252298 | 0.83 | HTR1A (0.61) | DRD2DRD3DRD4ADRA1A | |
| SCHEMBL14987761 | 0.82 | SLC6A2 (0.76) | SLC6A2SLC6A4DRD2DRD3DRD4 | |
| SCHEMBL15601753 | 0.82 | DRD2 (0.74) | SLC6A2SLC6A4DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | claimed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | claimed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | DRD2, AVPR2, NTSR2 | SLC6A2 49/4885SLC6A4 210/4885DRD2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.